Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543648 | 0.90 | ADRA2A (0.53) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2542670 | 0.81 | KDM4E (0.53) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2543201 | 0.81 | LRRK2 (0.43) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL7185783 | 0.81 | EGFR (0.53) | EGFR | |
| SCHEMBL27252329 | 0.73 | TNF (0.40) | KDM4EALDH1A1ABCG2 | |
| SCHEMBL2543205 | 0.72 | CDK1 (0.46) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2542673 | 0.72 | KDM4E (0.53) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL29393606 | 0.71 | CDK1 (0.49) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL10720 | 0.70 | IMPDH2 (0.47) | CHEK1KDM4EMAPTALDH1A1APEX1 | |
| Hydrochloric Acid SCHEMBL3671410 | 0.69 | IMPDH2 (0.46) | CHEK1KDM4EMAPTALDH1A1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | claimed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | claimed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | claimed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ADRA2A 4681/4885ADRA2C 4364/4885ADRA1D 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.